Pseudoprogression on ¹⁸F-FDG PET/CT Imaging of Malignant Melanoma Treated with Nivolumab

• OKUHIRA Hisako

  Department of Dermatology, Wakayama Medical University

• SHIMA Tomoko

  Department of Dermatology, Wakayama Medical University

• INABA Yutaka

  Department of Dermatology, Wakayama Medical University

• DOI Naotaka

  Department of Dermatology, Wakayama Medical University

• KUNIMOTO Kayo

  Department of Dermatology, Wakayama Medical University

• MIKITA Naoya

  Department of Dermatology, Wakayama Medical University

• FURUKAWA Fukumi

  Department of Dermatology, Wakayama Medical University

• YAMAMOTO Yuki

  Department of Dermatology, Wakayama Medical University

Bibliographic Information

Other Title

• ニボルマブによりpseudoprogressionを起こしたと思われた悪性黒色腫の当科での検討

Abstract

Pseudoprogression is an atypical response after cancer treatment, and is defined as a temporary increase in the total tumor burden. Previously, pseudoprogression has often been reported after combination treatment of chemotherapy and radiotherapy, but recently, it has been reported after immune checkpoint blockade therapy, such as after treatment with the PD-1 inhibitor nivolumab. Pseudoprogression is shown as nodules on computed tomography (CT) imaging, which indicates T cell infiltration and extensive necrosis. In our study, we explored pseudoprogression in 8 malignant melanoma patients using ¹⁸F-FDG PET/CT imaging in our department.[Skin Cancer (Japan) 2016 ; 31 : 110-113]

Journal

• Skin Cancer

  Skin Cancer 31 (2), 110-113, 2016

  The Japanese Skin Cancer Society

Keywords

• Melanoma
• Pseudoprogression
• PD-1
• Nivolumab

Details

• CRID: 1390282679313933568
• NII Article ID: 130005268055
• DOI: 10.5227/skincancer.31.110
• ISSN: 18843549
• ISSN: 09153535
• Web Site: https://www.jstage.jst.go.jp/article/skincancer/31/2/31_110/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2017208583
• Text Lang: ja
• Data Source:
  • JaLC
  • Crossref
  • CiNii Articles
• Abstract License Flag: Disallowed